Carbidopa-Levodopa in 2026: What's the Current Supply Situation?

If you or a loved one depends on Carbidopa-Levodopa to manage Parkinson's disease, you've probably felt the impact of supply issues at some point. Shortages of this essential medication have come and gone since 2011, and patients are understandably anxious about whether they'll be able to fill their next prescription.

Here's what you need to know about Carbidopa-Levodopa supply, pricing, and your options in 2026.

Is Carbidopa-Levodopa Still in Shortage?

The picture is mixed. Here's the breakdown by formulation:

• Immediate-release tablets (generic Sinemet): Generally available from multiple manufacturers in the most common strengths (25/100 mg, 25/250 mg, 10/100 mg). However, intermittent stock-outs still occur at individual pharmacies, particularly in rural areas or during peak demand periods.
• Extended-release tablets (generic Sinemet CR): More affected by shortages. Accord discontinued its 25/100 mg ER tablets, leaving fewer manufacturers in the market. The 50/200 mg strength is more reliably available.
• Orally disintegrating tablets: Sun Pharma discontinued its ODT formulation. Availability is limited.
• Branded products (Rytary, Crexont, Duopa): Generally available through specialty pharmacies, though they come at significantly higher cost.

For the latest on why Carbidopa-Levodopa can be hard to find, see our detailed explainer.

Why Has Carbidopa-Levodopa Been Hard to Find?

Several factors have contributed to recurring supply disruptions:

• Manufacturer consolidation: As some generic manufacturers exit the market, fewer suppliers remain to meet demand.
• Thin profit margins: Generic Carbidopa-Levodopa is inexpensive ($9–$85 for a 90-day supply), which means manufacturers earn less per unit and have less incentive to maintain buffer stock.
• Quality and compliance issues: FDA inspections and manufacturing delays have forced temporary production shutdowns at some facilities.
• Rising demand: With nearly 1 million Americans living with Parkinson's disease — a number projected to reach 1.2 million by 2030 — demand continues to grow.

What Does Carbidopa-Levodopa Cost in 2026?

Generic Carbidopa-Levodopa remains one of the more affordable Parkinson's medications:

• Without insurance or coupons: Approximately $30–$85 for 90 tablets of the 25/100 mg immediate-release strength.
• With a discount coupon (SingleCare, GoodRx): As low as $9–$24 for the same supply.
• Extended-release generic: Around $15–$40 for 90 tablets with coupons.
• Branded Rytary: $700–$1,500+ per month without insurance.
• Carbidopa alone (Lodosyn): Can exceed $1,300 without coupons — with coupons, around $65.

For a comprehensive guide to cutting costs, read our article on how to save money on Carbidopa.

New Options and Developments

There are some positive developments for Parkinson's patients in 2026:

• Crexont: This newer extended-release capsule formulation of Carbidopa-Levodopa offers more consistent plasma levels throughout the day. It's an additional option when other ER formulations are scarce.
• Dhivy: Another formulation option that may offer improved availability compared to traditional generic tablets.
• Telehealth access: More neurologists and movement disorder specialists now offer telehealth visits, making it easier to get prescription adjustments quickly when supply issues arise. Learn how to find a doctor who prescribes Carbidopa near you.

How to Find Carbidopa-Levodopa in Stock

If your pharmacy is out of stock, take these steps:

1. Search on Medfinder to see which pharmacies near you have your exact medication in stock.
2. Try independent pharmacies — they often use different wholesalers and may have stock when chains don't.
3. Ask your pharmacist to backorder — restocking may take just 1–2 business days.
4. Talk to your neurologist about temporary alternatives or formulation switches.
5. Consider mail-order pharmacies for 90-day supplies.

For more strategies, read our full guide on how to find Carbidopa in stock near you.

Final Thoughts

Carbidopa-Levodopa shortages are an ongoing challenge, but the standard immediate-release tablets remain available from several manufacturers in 2026. The biggest risks are with extended-release and specialty formulations, where manufacturer exits have narrowed the field.

Stay proactive: keep a small buffer supply when possible, use tools like Medfinder to monitor availability, and maintain an open line of communication with your neurologist. For information on side effects to watch for, see our guide on Carbidopa side effects.